Human EGFR is overexpressed in nearly all subtypes of breast cancer; however, it is more frequently overexpressed in triple-negative or basal-type breast cancers, which are highly aggressive and resistant to existing therapies [2–4]. This evidence concerns the gene EGFR and breast cancer.